EmblemHealth says Alexion monopolized US market for rare blood disease treatment
EmblemHealth has brought US antitrust claims against Alexion Pharmaceuticals, alleging the drug company and its wholly owned subsidiary AstraZeneca unlawfully delayed the introduction of biosimilar competition to its blockbuster drug Soliris...To view the full article, register now.
Already a subscriber? Click here to view full article